In vivo – personalized
cancer therapies
In vivo cell reprogramming in AML and beyond
Modiblast pursues a novel in vivo cell reprogramming approach to treat hematological malignancies and other cancers. Our proprietary strategy aims to drive innate & adaptive immune responses and establish memory cells. With our lead pipeline program progressing towards a first clinical trial in acute myeloid leukemia (AML), we are in the process of raising our seed round. Our long-term vision is to establish a cancer backbone therapy capable of prolonging phases in remission. We aim to enable patients to self-administer this novel drug combination at home, drastically improving their quality of life.
Modiblast won the Startup Spotlight competition at the BIO-Europe 2022, was recognized as one of eight finalists of the 9th BioRiver Boost! Start-Up Competition 2022, and also ranked among the 20 Finalists of the WECONOMY Start-Up Competition 2022.
Increasing need for maintenance therapy
While progress has been made, still about 80% of all AML patients in remission relapse within 2 years. Only 30% survive more than 5 years after diagnosis. We aim to address the strong future need for remission-extending maintenance therapies.Key benefits of our approach
Personalization
Triggers a personalized immune response against the tumor in vivo.
Logistics
Avoids known challenges limiting ex vivo cell- and gene therapies.
Quality of Life
Potential for a self-administrable formulation and once-daily dosing regimen.
Project Milestones and Outlook
Our first program, MB101, aims for fixed-dose combination of granulocyte-macro-phage colony stimulation factor (GM-CSF), and a „danger signal“, prostaglandin E1 (PGE1).
Fostering hematological recovery
Patient data hint at MB101’s ability to restore neutrophil and thrombocyte counts in heavily pre-treated patients, potentially avoiding neutropenia, thrombocytopenia, and the associated need for transfusions. A positive effect on hematological recovery could enable progressing into earlier lines of treatment or an expanded treatment label.
Latest Press Release
May 17, 2023
Modiblast MB101 program passes BfArM scientific advice and pre-CTA meeting without objections
Modiblast announced that its lead development program MB101 has passed a recent scientific advice and pre-CTA meeting with the BfArM without objections.
Learn more
Upcoming Events
Sep 25-26, 2024
24th Annual Biotech in Europe Forum
Meet Modiblast CEO Helga Schmetzer at Sachs Associates’ 24th Annual Biotech in Europe Forum in Basel.
Learn more